Chronic Thromboembolic Pulmonary Hypertension
84
17
18
27
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.0%
5 terminated out of 84 trials
84.4%
-2.1% vs benchmark
8%
7 trials in Phase 3/4
26%
7 of 27 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 27 completed trials
Clinical Trials (84)
Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism
129Xe MRI Cardiopulmonary
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH
Dapagliflozin in Pulmonary Arterial Hypertension
Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension
Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)
Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism
Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Hypertension Association Registry
Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
Inspiratory Muscle Training in Pulmonary Hypertension
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
Pulmonary Hypertension Biorepository and Registry
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Chronic Thromboembolic Disease Registry
Switching of Sildenafil to Riociguat in CTEPH Patients
TrEatment Approach in the Multimodal Era Registry
Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.